10-Q: P&G Q1 Earnings Show Sales Growth Amidst Cost Pressures

The Procter & Gamble Company reported a 4.0% increase in net sales for the first quarter of fiscal year 2027, reaching $23.3 billion, driven by volume and pricing, while navigating higher commodity costs.

Summary

• The Procter & Gamble Company (P&G) reported net sales of $23.3 billion for the three months ended September 30, 2026, a 4.0% increase from the prior year.
• Diluted Earnings Per Share (EPS) rose by 1% to $1.97, with Core EPS also increasing by 1% to $2.00.
• Operating cash flow was $5.8 billion, and free cash flow was $4.4 billion, resulting in a free cash flow productivity of 93%.
• The company completed the acquisition of Thorne, a wellness and supplement brand, for $3.9 billion on October 1, 2026.
• P&G announced a portfolio and productivity plan in June 2025, expecting to incur approximately $2.0 billion in before-tax restructuring costs over two years, with up to 7,000 non-manufacturing overhead personnel reductions planned by the end of fiscal 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as generally positive, reflecting stable financial performance and strategic initiatives, though with some areas of cost pressure.

Positives

• Net sales increased by 4.0% to $23.3 billion, driven by a 2.4% unit volume increase, favorable geographic mix, and higher pricing.
• Organic sales grew by 4.0%, indicating underlying business strength.
• Diluted EPS increased by 1% to $1.97, and Core EPS also saw a 1% increase to $2.00.
• Operating cash flow of $5.8 billion and free cash flow of $4.4 billion demonstrate strong cash generation.
• Free cash flow productivity of 93% is a positive indicator of efficient cash conversion.
• The acquisition of Thorne for $3.9 billion is a strategic move to expand into the wellness and supplement category.

Negatives

• Gross margin decreased by 160 basis points to 49.8% due to higher commodity costs (140 bps), product/packaging investments (140 bps), and unfavorable product mix (50 bps).
• Net earnings decreased by 1% to $4.8 billion, and net earnings attributable to Procter & Gamble decreased by $19 million.
• Certain segments, like Baby, Feminine & Family Care, experienced a 4% decrease in net earnings due to margin compression.
• The effective income tax rate increased slightly to 21.0% from 20.8%.

Risks

• Exposure to global macroeconomic factors, geopolitical tensions, and government policies, including currency fluctuations, market volatility, and tariffs.
• Commodity and supply chain cost fluctuations, including prices of oil-derived materials and pulp, can directly affect costs.
• Potential for increased costs due to legal or regulatory requirements and sustainability initiatives.
• Changes in U.S. and foreign government legislative, regulatory, or enforcement policies, including tax policy changes.
• The Gillette indefinite-lived intangible asset is susceptible to impairment risk due to adverse changes in the business or macroeconomic environment.
• Disruptions in manufacturing, supply, and distribution operations can lead to increased costs.

Future Outlook

The company is executing a portfolio and productivity plan aimed at streamlining its operations and improving its cost structure, which includes significant restructuring costs and personnel reductions over the next two years. The acquisition of Thorne is expected to be integrated into the Personal Health Care segment, with its results becoming material starting in the fourth quarter of fiscal 2027.

Management Comments

• "Net sales were $23.3 billion, an increase of $890 million, or 4.0%, versus the prior year period."
• "Diluted EPS increased 1% to $1.97. Core EPS, which represents diluted EPS excluding charges for incremental restructuring, increased 1% to $2.00."
• "Operating cash flow was $5.8 billion. Free cash flow, which is defined as operating cash flow less capital expenditures, was $4.4 billion. Free cash flow productivity, which is defined as free cash flow as a percentage of net earnings, was 93%."
• "The Company completed the acquisition of Thorne, a premium wellness and supplement brand... for $3.9 billion in an all-cash transaction."
• "The Company expects to incur approximately $2.0 billion in before-tax restructuring costs over two years."

Industry Context

StockSavvy.ai notes that P&G's performance aligns with broader trends in the consumer staples sector, which is experiencing moderate sales growth driven by pricing and volume, but also facing inflationary pressures on commodity and supply chain costs. The strategic acquisition of Thorne reflects a continued industry focus on expanding into higher-growth, higher-margin categories like health and wellness.

Comparison to Industry Standards

• P&G's organic sales growth of 4.0% is generally in line with or slightly above the average for large-cap consumer staples companies, which often aim for low to mid-single-digit growth.
• The gross margin decline due to commodity costs is a common challenge across the industry, impacting many competitors.
• The company's free cash flow productivity of 93% is a strong metric, often exceeding industry benchmarks for mature consumer goods companies.
• Competitors like Unilever and Colgate-Palmolive also face similar challenges with input cost inflation and are implementing productivity measures and strategic portfolio adjustments.

Legal Proceedings

• The company is subject to various legal proceedings and claims, including antitrust, product liability, advertising, contracts, environmental, patent, trademark, labor, employment, and tax matters.
• Management and counsel believe the ultimate resolution of these matters will not materially affect the company's financial position, results of operations, or cash flows.
• The company is also subject to contingencies related to environmental remediation, which are not expected to materially affect financial results.

Stakeholder Impact

• Shareholders: The modest increase in EPS and continued dividend payments (implied by cash flow allocation) are generally positive. However, the impact of restructuring costs and potential margin pressures could be a concern.
• Employees: The plan includes a reduction of up to 7,000 non-manufacturing overhead personnel, which will impact those employees.
• Suppliers: The company continues its program to negotiate extended payment terms with suppliers, with amounts due to SCF participants remaining significant.
• Creditors: The company's strong debt ratings and access to commercial paper and bond markets suggest continued ability to meet debt obligations.

Next Steps

• Continue execution of the portfolio and productivity plan, including personnel reductions and business/market exits.
• Integrate the acquired Thorne brand into the Personal Health Care segment.
• Finalize the accounting and fair value determination for the Thorne acquisition by the end of the three months ending December 31, 2026.
• Continue to manage global financial and economic risks, including currency fluctuations and market volatility.
• Focus on supply chain optimization and cost management initiatives.

Key Dates

Recommendation

The filing shows stable performance with modest sales and EPS growth, but also highlights increasing cost pressures and significant restructuring efforts. While the acquisition of Thorne is a positive strategic move, the near-term impact of restructuring and cost inflation warrants a cautious approach. The company's strong market position and cash flow generation support a 'hold' rating, pending clearer visibility on the benefits of the restructuring and integration of Thorne.

Keywords

Consumer Goods, Quarterly Report, Financial Results, Sales Growth, Earnings Per Share, Cash Flow, Acquisition, Restructuring